Navneet Natt

Navneet Natt

Auto-generated profile, based on publicly available information

Navneet Natt

Department of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL 60637

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
NNNavneet Natt
Navneet Natt
FMFaith Michael
Faith Michael
HMHope Michael
Hope Michael
SDSacha Dubois
Sacha Dubois
AMAhmed Al Mazrou’i
Ahmed Al Mazrou’i
Background and Aims. While endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC), there is conflicting data on associated adverse events. The aims of this systematic review and meta-analysis are to (1) compare ERCP-related adverse events in patients with and without PSC and (2) determine risk factors for ERCP-related adverse events in PSC. Methods. Embase, PubMed, and CENTRAL were searched between January 1, 2000, and May 12, 2021. Eligible studies included adults with PSC undergoing ERCP and reported at least one ERCP-related adverse event (cholangitis, pancreatitis, bleeding, and perforation) or an associated risk factor. The risk of bias was assessed with the Newcastle-Ottawa scale and Cochrane Risk of Bias 2. Raw event rates were used to calculate odds ratios (ORs) and then pooled using random-effects models. Results. Twenty studies met eligibility criteria, of which four were included in a meta-analysis comparing post-ERCP adverse events in patients with PSC (n = 715) to those without PSC (n = 9979). We found a significant threefold increase in the 30-day odds of cholangitis in PSC compared to those without (OR 3.263, 95% CI 1.076–9.896; ). However, there were no significant differences in post-ERCP pancreatitis (PEP), bleeding, or perforation. Due to limitations in primary data, only risk factors contributing to PEP could be analyzed. Accidental passage of the guidewire into the pancreatic duct (OR 7.444, 95% CI 3.328–16.651; ; I2 = 65.0%) and biliary sphincterotomy (OR 4.802, 95% CI 1.916–12.033; ; I2 = 73.1%) were associated with higher odds of PEP in a second meta-analysis including five studies. Conclusions. In the context of limited comparative data and heterogeneity, PSC patients undergoing ERCP have higher odds of cholangitis despite the majority receiving antibiotics. Additionally, accidental wire passage and biliary sphincterotomy increased the odds of PEP. Future studies on ERCP-related risks and preventive strategies are needed.

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MVMarina Vainder
Marina Vainder
NNNavneet Natt
Navneet Natt
PSParastoo Sayyar
Parastoo Sayyar
ASAmbreen Syeda
Ambreen Syeda
RARizwana Ashraf
Rizwana Ashraf
RDRohan D'Souza
Rohan D'Souza
Objective: To determine whether a third-trimester drop in insulin requirements in pregnant people with pre-existing diabetes is associated with a subsequent occurrence of adverse pregnancy outcomes. Research Design and Methods: We conducted a retrospective cohort study of patients with type 1 and 2 diabetes who were followed at a tertiary referral center in Toronto, Canada. We collected data on insulin dosing in the third trimester (after 28 weeks of pregnancy) and compared outcomes in those with and without a third-trimester drop of 15% or more in their total insulin requirements. Our primary outcome was a composite of stillbirth, spontaneous preterm birth or preterm premature rupture of membranes, and iatrogenic preterm birth or cesarean birth for fetal wellbeing concerns, occurring following the drop in insulin requirements. We conducted regression analyses controlling for early pregnancy glycosylated hemoglobin, body mass index, and diabetes-related microvascular disease, and presented results as odds ratios (OR) with 95% confidence intervals (95%CI). Results: We included 350 pregnant people—146 with type 1 and 204 with type 2 diabetes. Of these, 54 (15.4%) had a third-trimester drop of 15% or more in their total insulin requirements. There was no difference in the primary outcome between groups (OR 0.97; 95% CI 0.41–2.10). Conclusions: Based on this single-center study, limited by sample size and analytic constraints, in people with pre-existing diabetes, a third-trimester drop of ≥15% in total insulin requirements was not associated with subsequent occurrence of adverse pregnancy outcomes. Larger prospective studies looking at associations between a drop in insulin requirements and subsequent occurrence of adverse pregnancy outcomes are necessary to inform meta-analyses and clinical decision making.

18 September 2026 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
NNNavneet Natt
Navneet Natt
ASAsher Shafrir
Asher Shafrir
ZFZachary Fine
Zachary Fine
AMAlex J Mathew
Alex J Mathew
MAMalek Ayoub
Malek Ayoub
DRDavid T Rubin
David T Rubin
Background: We present a prospective evaluation of the effectiveness and safety of subcutaneous (SC) vedolizumab in patients with inflammatory bowel disease (IBD) who transitioned from standard or dose-escalated intravenous (IV) maintenance to SC vedolizumab and those who started SC vedolizumab following IV induction. Methods: We prospectively evaluated adults with IBD treated with SC vedolizumab at the University of Chicago from September 2023 to December 2025. We examined the following outcomes: treatment persistence, maintenance of clinical and biochemical remission in those in remission at time of switch, and adverse events (AEs). Outcomes were stratified by baseline IV vedolizumab dosing and clinical disease activity. Results: We included 86 patients who switched from IV maintenance to SC vedolizumab, of whom 25 were on dose-escalated IV therapy. One-year treatment persistence was 82.6%, regardless of IV dosing or clinical disease activity. Of those in clinical remission, 97.5% remained in clinical remission at 1 year. Of those with biochemical data available, 95.8% maintained normalization of C-reactive protein (CRP) and 100% maintained normalization of fecal calprotectin (FCP). We included a second exploratory group with 18 patients who received SC vedolizumab after 2 IV induction doses. Forty-five patients across Groups 1 and 2 experienced 51 AEs, most commonly IBD flare (n = 19) and injection site reactions (ISRs) (n = 18). Conclusion: Transitioning from IV to SC vedolizumab was associated with high treatment persistence (82.6%) and sustained clinical remission (97.5%) at 1 year. The findings were similar in a small cohort of patients on prior dose-escalated IV vedolizumab. Potential risks include ISRs and relapse of IBD.

3 September 2025 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
NNNavneet Natt
Navneet Natt
TMTyrel Jones May
Tyrel Jones May
GMGurpreet Malhi
Gurpreet Malhi
JDJennifer Dumond
Jennifer Dumond
AGAliya Gulamhusein
Aliya Gulamhusein
PTParul Tandon
Parul Tandon
Purpose: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that frequently coexists with inflammatory bowel disease (IBD). The risk of infections in patients with concurrent PSC-IBD remains unclear. The aim of this study was to identify the event rate of infections and associated risk factors in PSC-IBD patients. Methods: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 12, 2024 for studies examining event rate or risk factors for infection in patients with PSC-IBD. The primary outcome was the event rate of all-cause and site-specific infections as well as infection-related mortality. The secondary outcome was risk factors for infection. Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI) comparing the event rate of all-cause infections in PSC-IBD patients to those with just PSC and just IBD. I2 values more than 50% suggested substantial heterogeneity. Results: Eighty-one studies were included. The pooled event rate of all-cause infections in patients with PSC-IBD was 25.1% (95% CI, 17.0%-33.2%, I2 = 99.2%). PSC-IBD patients had significantly increased odds of all-cause infection (OR 3.67, 95% CI, 2.07-6.52, I2 = 41.9%), sepsis (OR 3.35, 95% CI, 2.29-4.91, I2 = 9.1%), and infection-related mortality (OR 11.25, 95% CI, 2.03-62.37, I2 = 0) compared to those with IBD but not those with PSC. Conclusion: Patients with PSC-IBD appear to be at increased risk of all-cause infection, sepsis, and mortality compared to those with IBD alone.